Our goal is to help ensure a healthy, safe, germ-free world.
Our versatile platform can permanently modify surface structures to
destroy viral, bacterial and fungal cells on contact.
Our portfolio of proprietary molecules render a wide range of materials 99.99% permanently biocidal
Demonstrating effectiveness across diverse industries and materials
Excellence in Science, Medicine & Industry
Former CEO WebMD
previously Senior executive at Merck
An experienced CEO with a strong track record of scaling early stage technology companies through high performance growth cycles, Wayne has demonstrated strong leadership in driving product innovation, brand leadership, business development and organizational transformation.
Wayne was CEO/President of WebMD from 2001-2012 where he built the company as the most recognized and trusted brand of health information for consumers and healthcare professionals. He led the company’s IPO in 2005 and grew the corp. over a to $600M revenues with a +$3B market cap over a 10-year period.
Most recently Wayne was CEO of DoubleVerify, an industry-leading digital data and analytics technology company. Wayne led the company’s explosive growth over an 8-year period from VC-backed start-up through successful private equity transition, increasing revenues and net margins over 12x.
Wayne has held executive positions with Merck & Co, MCI Telecommunications, as well as board Director positions with several public and private companies.
Wayne serves on the advisory board of the LeBow College of Business at Drexel University and holds an MBA from St Joseph’s University in Philadelphia.
Fellowship trained spine surgeon, currently Yale New Haven
Biocidal coating chemistry, biocompatibility research
Dr. Houssam Bouloussa is a fellowship-trained pediatric and adult orthopaedic spine surgeon based in New Haven, CT (USA).
He graduated from Bordeaux University medical school (Bordeaux, France) in 2010 and completed his orthopaedic surgery residency (research-track) at the prestigious Greater Paris University Hospitals (APHP, Paris, France) in 2016. Prolific in both basic and clinical research, he has co-authored numerous publications and presented his research at more than 20 international meetings. He is co-inventor of the first DeBogy technology.
As Co-Founder and VP Operations of DeBogy Molecular, he adds his unique bridging knowledge between surface chemistry, bacteriology, cellular biology, pre-clinical models and surgery.
Dr. Bouloussa is a tireless traveler and fluently speaks three languages (English, French and Arabic). He spends his time between the United States and France.
Board-certified radiologist, early stage investor
Dr. Delaunay has been practicing Radiology for more than two decades in both academic and private settings.
He is Ivy League trained in Europe and the USA.
He taught radiology at various institutions including Cornell University, University of Virginia, University of Paris and Michigan State.
A prolific entrepreneur, he was an investing founder of Imaging Advantage, a premier teleradiology firm, since sold to Goldman Sachs.
As Corporate Strategy of DeBogy Molecular he brings a strategic vision and investment experience for development of extraordinary promising molecules in anti infectious coating and protection as well as his solid team of associate PhDs and MDs.
He spends his time between Michigan, New York and Paris.
Fellowship trained Orthopedic surgeon currently at
NYU Langone Hospital, NY
Highly-cited physician and scientist
Dr. Emmanuel Gibon is a hip and knee arthroplasty surgeon who has been practicing in France, Canada and now the United States. He currently practices academic orthopedics at NYU in the USA.
Early in his career he completed two research fellowships at Stanford University and then obtained his PhD in biomaterials at the University of Paris.
A productive researcher, Dr. Gibon has published numerous scientific articles and book chapters.
As Co-Founder and VP Research & Academic Partnerships of DeBogy Molecular, he adds his solid scientific background and experience in joint replacement to design innovative & ingenious antibacterial coatings.
Dr. Gibon devotes his time between the United States and France.
Internationally recognized spine surgeon and key
opinion leader on minimally invasive spine surgery
Former co-chief of orthopedic spine surgery at the Yale School of Medicine. Principal investigator for multiple FDA and non-FDA clinical trials.
Dr. James J. Yue is immediate prior co-chief of the orthopaedic spine surgery section at the Yale School of Medicine. He is founder of the Yale Spine Fellowship. He completed his undergraduate studies at Harvard University in Cambridge, MA where is received an A.B. degree with Magna Cum Laude honors in biology. He completed his medical school training at the Northwestern University School of Medicine in Chicago, IL and orthopaedic surgery residency at Case Western Reserve University Hospitals of Cleveland, in Cleveland, OH. He completed two post residency fellowships, the first at the RA Cowley Shock Trauma Hospital in Baltimore, MD and the second at the Queen’s Medical Centre in Nottingham, UK.
He has been the Principal Investigator/Co-Investigator on multiple FDA and non FDA clinical trials for disc replacement and endoscopic spine surgery. He is the past Chair of the Education Committee for the International Society for the Advancement of Spine Surgery and IITTSS spine society. He is the current the ISASS AMA CPT delegate.
He has published and presented over 100 scientific articles and abstracts and 4 major spinal surgery textbooks. He is a journal reviewer for several international spine surgery journals.
He is currently in private practice in Connecticut and an Associate Professor in the Frank H. Netter School of Medicine Quinnipiac University where he serves on the Dean’s Council.
Former Assoc Professor of Chemistry, Curie Institute, Paris
Internationally renowned and published research scientist in the fields of physical and surface chemistry
Dr. Othman Bouloussa is an internationally renowned and experienced research scientist in the fields of physical chemistry and surface chemistry. As a former associate professor at the Pierre and Marie Curie University in Paris, France, he has a 40-year experience in physical chemistry and surface chemistry.
He authored over 50 publications in prestigious journals, and spoke at numerous international meetings. He is fully dedicated to his students and peers: he directed over twenty PhD theses, taught physical chemistry and organic chemistry to hundreds of future secondary school teachers, and reviewed over a hundred scientific papers.
“Less is More”
Aware of the applicability limitations of current academic research in terms of feasibility, costs and scalability, he always enjoyed conceptualizing simple and efficient chemistry to render it appealing to the industry. His expertise was notably requested by L’Oréal, Sony, and Total, among numerous prominent industrial actors. In addition, Dr. Othman Bouloussa obtained three granted patents.
He spends his time between Bordeaux, France and Kolkata, India.
Former resident ER, Rouen, France
Dr. Durand obtained her MD at the University of Rouen (Rouen, France) in 2017. During her time in medical school, she raised over 25,000€ for local, national and international community-based nonprofit associations and organizations. She appeared on numerous French national radio, newspapers, and television programs as an association vice-president and medical doctor.
As a Co-Founder and VP Marketing of DeBogy Molecular, she coordinates members to identify and reach development milestones. Thanks to her background as an award-winning campaign organizer, she is currently building our web presence.
Dr. Durand resides in New Haven, CT and frequently travels across the USA.